Title: A molecular basis for nonsecretory myeloma

Authors: Daniel Coriu,1,3 Kristal Weaver,1 Maria Schell,1 Manfred Eulitz,1,2 Charles L. Murphy,1 Deborah T. Weiss,1 and Alan Solomon1

Affiliation: From the 1Human Immunology and Cancer Program, Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN; 2GSF Institute of Molecular Immunology, Munich, Germany; and 3University of Medicine “Carol Davila,” Bucharest, Romania

Running title: Nonsecretory myeloma

Word count: abstract: 147; text: 1342

Scientific heading: Immunobiology

Support: Supported in part by USPHS Research Grant CA10056 from the National Cancer Institute and the Aslan Foundation. D.C. and M.E. were Harry and Elsa Jiler American Cancer Society International Visiting Scientists. A.S. is an American Cancer Society Clinical Research Professor.

Corresponding author: Alan Solomon, MD, University of Tennessee Graduate School of Medicine, 1924 Alcoa Highway, Knoxville, TN 37920

Telephone: (865) 544-9165

Fax: (865) 544-6865

e-mail: asolomon@mc.utmck.edu
Abstract

The biosynthesis of aberrant Ig polypeptides by monoclonal plasma cells has been implicated in the pathogenesis of nonsecretory myeloma. Our studies of a patient with this disorder indeed have demonstrated the presence of abnormal λ-light chains that resulted from a frameshift mutation in nucleotides encoding the constant region of the molecule. As a consequence of a 2-base deletion in codon 187 and loss of the normal stop codon, this portion of the λ-chain was composed of 128 amino acids (rather than the expected 106), with a completely anomalous sequence after position 187 that included absence of the cysteines required for intra- and inter-chain disulfide bonds. The unusual primary structure of this component was confirmed by mass spectrometric and amino acid sequence analyses of cytoplasmic protein extracts. Our studies provide the first evidence that human nonsecretory myeloma may result from an alteration in the light chain constant region.
**Introduction**

Nonsecretory myeloma (NSM) is defined by the absence of serum and/or urinary monoclonal Igs in patients who otherwise manifest features typically found in multiple myeloma (MM).\(^1,2\) This condition, which occurs in ~1 to 5% of patients with MM, results either from the inability of malignant plasma cells to synthesize Ig (i.e., non-producer) or, more commonly, the failure of such components to be exported from the cells (i.e., nonsecretor). In the latter case, it has been assumed that the protein undergoes intracellular proteolysis due to a structural defect in the Ig and, as a consequence, is not excreted. However, there is only limited information regarding the molecular factors that might account for this phenomenon.\(^3-7\) We now report our finding that the plasma cells of an individual with NSM indeed synthesized aberrant monoclonal light chains that resulted from a somatic mutation in the gene encoding the constant (C\(_L\)) region of the molecule. Our studies provide the first conclusive evidence that an abnormality in this portion of the light chain may be implicated in the pathogenesis of this disorder.

**Materials and methods**

**Protein analyses**

Serum IgG, IgA, and IgM proteins were quantitated with the Synchron LX20 Clinical System (Beckman Coulter, Fullerton, CA) and the concentration of free κ and λ light chains determined by ELISA, using our highly specific monoclonal antibodies (mAbs),\(^8\) as well as by nephelometry (Free Lite®, The Binding Site, Birmingham, England) with polyclonal reagents.\(^9\) For detection of monotypic Igs, serum was diluted 1:10 and subjected to immunofixation electrophoresis using the Paragon system (Beckman, Norcross, GA), according to the procedure specified by the manufacturer. Undiluted samples also were examined in similar fashion, as were unconcentrated
urine specimens and 24-hour collections that had been dialyzed extensively against distilled 
water, lyophilized, and reconstituted to a protein concentration of 100 mg/ml.\textsuperscript{10}

**Immunocytochemistry**

Bone-marrow plasma cells were isolated and immunostained with our murine mAbs specific for 
human light-chain variable region (V\textsubscript{L}) subgroups\textsuperscript{11} and for total (heavy chain-bound) and free 
(unbound) κ and λ polypeptides,\textsuperscript{8} as well as with mouse anti-human plasma cell (Dako, 
Carpinteria, CA) and rabbit anti-human γ, α, μ, and δ heavy-chain antisera (Biosource, 
Camarillo, CA).

**RNA preparation and reverse transcription–polymerase chain reaction (RT-PCR) 
amplification**

Total RNA was extracted from plasma cells with the PURESCRIPT RNA isolation kit (Gentra, 
Minneapolis, MN) and transcribed with both oligo (dT)\textsubscript{15} and random primers, using reverse 
transcriptase (Promega, Madison, WI) in a single reaction. First strand DNA was amplified by 
forward and reverse primers specifying the first and last 7 amino acid residues of a prototypic κ\textsubscript{1} 
light chain.\textsuperscript{12} The PCR products were cloned using the perfectly blunt cloning kit with the 
pSTBlue-1 vector (Novagen, Madison, WI) and the colonies screened by PCR. Plasmids were 
isolated from candidate clones using the Quantum Miniprep kit (Bio-Rad, Richmond, CA), 
further screened by EcoRI digestion to confirm insert size, and sequenced in both directions. 
The nucleic acid and deduced protein sequences were compared to the Genbank database.
DNA analysis

Genomic DNA was obtained from peripheral blood leukocytes using the PUREGENE DNA isolation kit (Gentra) and the $C_\kappa$-encoding gene was amplified by PCR\textsuperscript{12} with upstream and downstream primers specifying the first 6 and last 7 amino acid residues, respectively.

Isolation and characterization of intracellular (non-secreted) light chains

Total cell lysates were prepared\textsuperscript{13} from bone marrow-derived plasma cells and analyzed by SDS/PAGE. The light chain-containing band identified by immunoblotting was reduced, alkylated, digested with trypsin, and the resultant peptides isolated and subjected to automated sequence analysis and tandem mass spectrometry (MS/MS).\textsuperscript{14}

Approval was obtained from the University of Tennessee Graduate School of Medicine’s and Mayo Clinic’s institutional review boards for these studies. Informed consent was provided according to the Declaration of Helsinki.

Results and discussion

The patient was a 74-year-old male who fulfilled the principal diagnostic criteria for NSM; namely, no monoclonal Igs were detected even in undiluted sera or highly concentrated urines and he exhibited the salient bone marrow and skeletal abnormalities associated with MM (80% plasma cells and extensive osteolytic lesions), as well as reduced levels of normal IgG, IgA, and IgM (514, 46, and 33 mg/dL, respectively). The hemoglobin concentration was 9.2 mg/dL; serum calcium, 15mg/dL; and creatinine, 3.0 mg/dL. Values for serum free $\kappa$– and $\lambda$–chains and the $\kappa/\lambda$ ratio, as measured using both specific monoclonal\textsuperscript{8} and polyclonal\textsuperscript{9} antibodies, were
within normal limits. The bone marrow was extensively infiltrated by CD56⁺, CD38⁺, and CD43⁺/CD19⁻ plasma cells that had the t(11;14) (q13;q32) translocation. Their monotypic nature was apparent in immunohistochemical analyses using highly-specific anti-Cₖ and -Vₖ mAbs that revealed the presence of cytoplasmic κ light chains that were classified as members of the Vₖ1 gene family. Notably, the κ immunoreactivity was evidenced only by the mAb with specificity for an epitope present on κ-chains linked covalently to Ig heavy chains by a disulfide bond. In contrast, these molecules were not recognized by the anti-free κ-chain mAb (Figure 1A) and, with rare exception, were not immunostained by anti-heavy chain antisera.

Analyses of cDNA cloned from the abnormal plasma cell population revealed that the deduced primary structure of the 108-residue Vₖ was most closely homologous to that encoded by the A20 Vₖ1 and the Jₖ3 germline genes, differing by 5 and 1 amino acids, respectively (G28D, N31T, I48M, A50T, Y91F; D105E). The sequence of nucleotides specifying the Cₖ was as expected until codon 187, where there was a 2-bp deletion (GA) that resulted in an extended, aberrant product due to loss of the normal TAG stop codon 215. Notably, this frameshift mutation was not present in the patient’s genomic DNA (Figure 2) where the deduced protein product consisted of the anticipated 106 amino acids, including cysteines (Cys) at positions 194 and 214.

The composition of the non-secreted cytoplasmic κ-light chains was established through chemical analyses of protein isolated from plasma cell lysates. As evidenced by SDS/PAGE, this component had an unusually high Mr of ~26 kDa, in contrast to a value of ~23 kDa found for a monomeric κ1 Bence Jones protein from a patient with MM (Figure 1B). In immunoblotting experiments, both light chains reacted with the anti-total κ-chain mAb, but only the MM-derived protein was recognized by the anti-free κ monoclonal reagent (no heavy chains
were detected in the plasma cell isolate). The complete primary structure of the non-secreted molecule, as predicted from the cDNA data, was verified by amino acid sequencing and MS/MS (Figure 1C). Importantly, peptides ST10, ST11, and ST12 had anomalous sequences after position 187 that resulted from the frameshift mutation and confirmed that the C\(\kappa\) extended 20 residues beyond position 214. Thus, a new C\(\kappa\) reverse primer was prepared (5’-AGCTGGAGGACCGCAATAG-3’) and used to re-clone plasma cell-derived cDNA where the 378 nucleotides encoding the entire C\(\kappa\), plus the stop codon (TGA), were identified. The deduced amino acid sequence of this gene product was identical to that of the isolated cytoplasmic protein (Figure 1C).

Heretofore, mutations in genes encoding human and murine V\(L_1\)s have been implicated as causal factors in NSM.\(^3\)-\(^6\),\(^15\) Notably, our studies provide the first evidence that an aberrant product of a mutated C\(_L\) gene also can be associated with this disorder. The primary sequence alterations that resulted from the frameshift mutation included loss of the cysteine residues normally present at positions 194 and 214 that are involved in formation of intra- and inter-chain disulfide bonds, respectively. Based on x-ray crystallography, V\(_L\) and C\(_L\) domains typically are folded into independent compact structures.\(^16\) Although such data are not available on the patient’s protein, it is likely that the absence of Cys194 profoundly disrupted the 3-dimensional features of this molecule, i.e., lack of the internal Cys146-Cys194 disulfide bond prevented formation of a normal, stable C\(_L\) (additionally, loss of Cys214 would render the light chain incapable of binding covalently with the cysteine in the first heavy-chain C domain). Since the intracellular fate and eventual secretion of light chains from plasma cells are dependent, in part, on the interaction of these molecules with the hsp 70 protein BiP, an endoplasmic reticulum molecular chaperone that functions to facilitate the delivery of malfolded Ig polypeptides to the
intracellular degradative machinery, we posit that the misfolded κ-chains were retained within the plasma cell cytosol and underwent proteosome-mediated proteolysis. Whether Ig light chains from other cases of NSM exhibit similar structural features (abnormalities) remains to be established.

Acknowledgements

We thank Sallie D. Macy, Teresa J. Williams, Dennis A. Wofenbarger, and Craig Wooliver for technical assistance, Ronda L. Reed for manuscript preparation, the University of Tennessee Molecular Biology Resource Facility for nucleotide sequence analyses, and Dr. Jerry A. Katzmann for the nephelometric free light chain assays. Approval was obtained from the University of Tennessee Graduate School of Medicine’s institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki.

References


Figure 1. Immunocytochemical analyses of plasma cells from the patient with NSM and chemical characterization of the non-secreted κ-light chains. (A) Reactivity of bone marrow-derived plasma cells. The primary reagents included a murine anti-plasma cell mAb and those
specific for free or bound human κ-light chains. (original magnification, x 400). (B) Coomassie blue-stained SDS/PAGE gel of protein contained in the plasma cell lysates (lane 1), molecular mass standards (lane 2), and a κ1 Bence Jones protein isolated from the urine of a patient with MM (lane 3). (C) Primary structure of the κ1 light chain isolated from plasma cell lysates. The N-terminal amino acid sequence was established directly and the remainder from tryptic peptides subjected to Edman degradation (ST) and mass spectrometry (MT). The residues in parentheses were deduced from cDNA cloned from the patient’s plasma cells. The junction between the V\_L and C\_L domains is as designated and the anomalous residues after position 187 are italicized.

![Image of protein sequence](image)

**Figure 2**
Coriu et al

Φορμέ 2. Χομπαρισον οφ τηε Χκ protein sequences after position 187, as predicted from plasma cell cDNA and genomic DNA. The 2-bp deletion (GA) present in the plasma cell cDNA and the positions of the stop codons (\*) are as indicated.
A molecular basis for nonsecretory myeloma

Daniel Coriu, Kristal Weaver, Maria Schell, Manfred Eulitz, Charles L Murphy, Deborah T Weiss and Alan Solomon